Prostate cancer risk assessment

Novel p2PSA marker more accurate than PSA testing

The effectiveness of PSA (prostate-specific antigen) screening on reducing prostate cancer mortality was given a boost in 2009 when the conclusive findings from the 10-year European Randomized Study of Screening for Prostate Cancer (ERSPC) -- the world’s largest prostate cancer screening study – were published.

Photo: Novel p2PSA marker more accurate than PSA testing
Photo: Novel p2PSA marker more accurate than PSA testing

From 1992, the ERSPC study randomized 162,000 men, aged 55 to 69, in seven European countries to either a screening arm or a control group. Those screened were given a blood test to detect PSA levels: if it was 3.0ng/ml or more, they were offered a biopsy. The study showed that PSA screening delivers a 20% reduction in mortality from prostate cancer.

However, separate ERSPC findings also confirm that ~30% of detected cancers actually have non-aggressive features and are ‘indolent’ or slow growing. That’s because PSA testing is sensitive but not specific. Dr Bernard Cook, group manager scientific and professional relations immunodiagnostics at Beckman Coulter, Inc., USA, has pointed out: ‘With limited ability to discriminate between cancer and benign disease, screening for prostate cancer with PSA remains contentious. While it can help detect some life-threatening tumours, the argument against it is the risk of patients suffering unnecessary and potentially harmful tests and treatment.’

With its new prostate disease marker, p2PSA, and the Prostate Health Index (phi) Beckman Coulter reports that it has made a significant breakthrough in improving the specificity of prostate cancer bio-marker assessment, which helps reduce unnecessary biopsies.

Named Access Hybritech p2PSA, the new marker measures the [-2]proPSA molecule, an isoform of free PSA. Studies have demonstrated that when p2PSA measurements are combined with Access Hy-britech PSA and free PSA measurements, the resulting index demonstrates a significant improvement in clinical specificity for prostate cancer detection, relative to PSA and % fPSA alone, in the PSA range 2–10 ng/mL in men >50 years and with non-suspicious digital rectal examination (DRE) findings.(1)

The Beckman Coulter Prostate Health Index is derived by combining the results of three automated blood tests, Access Hybritech PSA, free PSA and the new p2PSA and is now available in Europe for use on the Beckman Coulter Access and UniCel DxI Immunoassay Systems. ‘When phi is installed, the system automatically calculates and reports the Prostate Health Index test results.’ John Blackwood, vice president and general manager at the Beckman Coulter Immunoassay Business Centre, said. ‘The phi score provides physicians with additional critical information to guide follow-up and treatment decisions for men with an elevated total PSA, including the challenging total PSA range of 2-4 ng/ml.’ The firm has also launched an educational website (ProstateHealthIndex.org) to inform patients, physicians and laboratory personnel about p2PSA and how to use the new Prostate Health Index. The website also provides links to credible medical resources, the latest unbiased scientific studies and details the benefits of the latest blood test.

21.05.2010

Read all latest stories

Related articles

Photo

Sponsored • Infection management

New sepsis marker speeds up detection and therapy

Sepsis is the cause of one in five deaths worldwide, killing nearly 11 million people each year, many of them children. It is also a major cause of disability, affecting millions more. To combat the…

Photo

Interview • Urinalysis for Covid-19 diagnostics

Automation to relieve pandemic pressure from laboratories

To provide a solution for the challenges of the coronavirus pandemic, Beckman Coulter recently launched the DxU Iris, a urinalysis solution which aims to improve lab workflows.

Photo

Sponsored • Lab equipment

Minimising laboratory errors with automation

Staffing shortages, increased testing volumes and the need to improve turnaround times have led to labs seeking to streamline services. Automation is the key, thanks to the role it plays in…

Related products

Beckman Coulter – Access 2 Immunoassay System

Immunoassays

Beckman Coulter – Access 2 Immunoassay System

Beckman Coulter Diagnostics
Beckman Coulter – Access Procalcitonin (PCT)

Immunoassays

Beckman Coulter – Access Procalcitonin (PCT)

Beckman Coulter Diagnostics
Beckman Coulter – AU5800 Series

Clinical Chemistry

Beckman Coulter – AU5800 Series

Beckman Coulter Diagnostics
Beckman Coulter – DxA 5000

Automation

Beckman Coulter – DxA 5000

Beckman Coulter Diagnostics
Beckman Coulter - DxA 5000 Fit

Automation

Beckman Coulter - DxA 5000 Fit

Beckman Coulter Diagnostics
Subscribe to Newsletter